Lupin receives highest ESG rating from CDP for climate change and water security

IMT News Desk
IMT News Desk
· 2 min read

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level

Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level.

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability and proactive initiatives aimed at mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This represents a substantial enhancement compared to Lupin’s 2024 ratings of ‘A-’ in both categories, as well as the ratings of ‘B’ in 2023 for climate and ‘C’ for water, thereby reflecting significant year-over-year progress.

Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin, said, “As a global pharma leader, we have significantly advanced our efforts to reduce environmental impact through innovation, collaboration, and transparency. We are proud to have earned CDP’s Double ‘A’ rating. CDP’s strict framework has helped shape and accelerate our climate initiatives, fostering ongoing progress. We are committed to establishing new sustainability standards and generating lasting value for our communities and the planet.”

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk
Cipla launches Yurpeak for treatment of obesity and Type 2 diabetes
Corporate
December 11, 2025

Cipla launches Yurpeak for treatment of obesity and Type 2 diabetes

Will be available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths Cipla announced the launch of Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) — two of the country’s most pressing health challenges. Cipla has the rights to distribute and promote […]
Article by: IMT News Desk